TRDA
Entrada Therapeutics Inc

166
Loading...
Loading...
News
all
press releases
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of -20.93% and -78.02%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock?
Entrada Therapeutics (TRDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·1mo ago
News Placeholder
Azenta Announces the Election of Dipal Doshi to its Board of Directors
Azenta Announces the Election of Dipal Doshi to its Board of Directors Azenta Announces the Election of Dipal Doshi to its Board of Directors PR Newswire BURLINGTON, Mass., Jan. 30, 2025 BURLINGTON...
PR Newswire·7mo ago
News Placeholder
The United Mitochondrial Disease Foundation Announces Inaugural Venture Philanthropy Investment; The Mito Fund Invests $500k in Pierrepont Therapeutics, Inc.
The United Mitochondrial Disease Foundation Announces Inaugural Venture Philanthropy Investment; The Mito Fund Invests $500k in Pierrepont Therapeutics, Inc. The United Mitochondrial Disease...
PR Newswire·1y ago
News Placeholder
Director Peter Kim Acquires 9,048 Shares of Entrada Therapeutics Inc (TRDA)
Related Stocks: TRDA...
GuruFocus·1y ago
News Placeholder
Entrada Therapeutics: Buy Rating on Strong Financials and Promising Clinical Pipeline
H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on TRDA stock, giving a Buy rating on March 13. Ram Selvaraju has given h...
TipRanks Financial Blog·1y ago
News Placeholder
Equities Analysts Offer Predictions for Entrada Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:TRDA)
Entrada Therapeutics, Inc. (NASDAQ:TRDA Free Report) Investment analysts at William Blair lowered their Q1 2024 earnings per share estimates for Entrada Therapeutics in a research...
Zolmax·1y ago
News Placeholder
Entrada Therapeutics Inc (TRDA) Reports Solid Financial Position and Advancements in Clinical Trials
Extended Cash Runway and Progress in Duchenne Muscular Dystrophy Treatments Mark 2023 MilestonesRelated Stocks: TRDA...
GuruFocus·1y ago
News Placeholder
Entrada Therapeutics expects cash to fund requirements through 2Q26
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·1y ago
News Placeholder
Entrada Therapeutics reports Q4 EPS (29c), consensus (17c)
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·1y ago

Latest TRDA News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.